In $1.36B biobuck deal with GSK, Mersana touts 'biggest preclinical ADC deal ever'

Kyle LaHucik

Senior Reporter

Days after Enhertu reeled in another FDA nod, with the first-ever green light for HER2-low breast cancer, another antibody drug conjugate biotech claims it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In $1.36B biobuck deal with GSK, Mersana touts 'biggest preclinical ADC deal ever'

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen offers to buy out struggling neuro partner Sage Therapeutics

The next generation of AI biotechs is here. Can they deliver on the hype?

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Chasing the next wave of obesity drugs, Metsera files for an IPO

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

In $1.36B biobuck deal with GSK, Mersana touts 'biggest preclinical ADC deal ever'